Articles tagged "Kidney"

2017 American Transplant Congress
Immunosuppressant Costs for Medicare Part D and Kidney Transplant Recipients Since the Introduction of Generic Formulations in an Incident Kidney Transplant Population.
M. Helmuth,¹ M. Turenne,¹ J. Park,² Q. Liu,¹ M. Oguntimein,³ S. Dutcher,³ R. Balkrishnan,⁴ J. Zee,¹ A. Smith,¹ A. Leichtman.¹
¹Arbor Research Collaborative for Health, Ann Arbor, MI; ²U of Michigan, Ann Arbor, MI; ³Food and Drug Administration, Silver Spring, MD; ⁴U of Virginia, Charlottesville, VA
Background: Substitution of generics (GEN) for brand name (BN) immunosuppressants (IS) has increased in kidney transplant recipients (KTR) since the introduction of GEN mycophenolate mofetil…
2017 American Transplant Congress
The Associations Between Immunosuppression Use, Loss of Medicare and Kidney Allograft Outcomes.
A. Hart,^1,2 S. Gustafson,² A. Wey,² N. Hadley,² A. Israni.²
¹Hennepin County Medical Center, Minneapolis; ²Scientific Registry of Transplant Recipients, Minneapolis
Medicare coverage for kidney transplant recipients aged <65 years in the US ends 3 years posttransplant, but a significant proportion of recipients remain on Medicare…
2017 American Transplant Congress
Factors Predicting 30-Day Hospital Readmission After Kidney Transplant.
J. Ostrem, M. Brokhof, N. Kenyon, E. Hollinger, S. Jensik, O. Olaitan, M. Hertl, N. Alvey.
Rush University Medical Center, Chicago, IL
Background: Hospital readmissions after kidney transplant have been associated with increased morbidity, mortality, decreased quality of life, and increased healthcare costs. The objective of this…
2017 American Transplant Congress
Evolution of Health Related Quality of Life (HRQOL) in Kidney Donors.
H. Ibrahim,¹ D. Berglund,¹ S. Jackson,² A. Matas.¹
¹U of MN, Mpls; ²M Health, Mpls
Most living donors (LDs) enjoy excellent HRQOL after donation. However, most studies addressing HRQOL in this group have ascertained HRQOL related outcomes only at one…
2017 American Transplant Congress
The Use of a Furosemide Stress Test (FST) for Assessment of Discarded Deceased Donor Kidneys in an Ex-Vivo Normothermic Perfusion Model.
I. Palma, Y. Smolin, S. Kabagambe, A. Perry, I. Palma, J. Sageshima, R. Perez.
Department of Surgery, UC Davis Medical Center, Sacramento, CA
Studies have shown that Ex-Vivo Normothermic Perfusion (EVNP) has the potential to assess viability and function of high-risk deceased donor kidneys. A diuretic response to…
2017 American Transplant Congress
Costimulatory Blockade in Delayed Graft Function.
J. Von Visger,¹ A. Diez,¹ U. Nori,¹ T. Pesavento,¹ R. Pelletier,² A. Rajab,² A. El Hinnawi,² H. Winters.³
¹Medicine, The Ohio State University, Columbus, OH; ²Surgery, The Ohio State University, Columbus, OH; ³Pharmacy, The Ohio State University, Columbus, OH
Background: Delayed graft function (DGF) contributes to higher risk of rejection, poorer graft survival, hospital length of stay (LOS), and other morbidities. Studies also suggest…
2017 American Transplant Congress
The IL6/Th17 Pathway May Play Different Roles in Cell-Mediated and Antibody-Mediated Alloimmune Injury in Renal Allografts.
D. Dobi,¹ Q. Tang,² S. Chandran,³ F. Vincenti,³ Z. Laszik.¹
¹Department of Pathology, University of California, San Francisco, San Francisco, CA; ²Department of Surgery, Division of Transplant Surgery, University of California, San Francisco, San Francisco, CA; ³Department of Medicine, Division of Nephrology, University of California, San Francisco, San Francisco, CA
Purpose. IL6 has been shown to contribute to shifting the balance between tolerogenic regulatory T cells and proinflammatory Th17 cells towards the latter. Our study…
2017 American Transplant Congress
Long-Term Liver and Kidney Survival Following Combined Liver-Kidney Transplantation, with or without Preformed Donor-Specific Antibodies.
A. Del Bello,¹ O. Bestard,² J. Visentin,³ N. Congy-Jolivet,¹ L. Couzi,³ M. Neau-Cransac,³ F. Jambon,³ N. Kamar.¹
¹Nephrology and Organ Transplant Department, CHU Toulouse, Toulouse, France; ²Nephrology and Kidney Transplant Department, Bellvitge University Hospital, Barcelona, Spain; ³Nephrology and Kidney Transplant Department, CHU Bordeaux, Bordeaux, France
Introduction: Successful kidney transplantation despite a positive crossmatch is well known after combined liver-kidney transplantation (CLKT). However, recently, concerns regarding the impact of preformed anti-HLA…
2017 American Transplant Congress
Post-Donation GFR Changes in Living Kidney Donors.
E. Poggio,¹ S. Arrigain,² J. Augustine,¹ S. Flechner,³ J. Schold.²
¹Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH; ²Qualitative Health Sciences, Cleveland Clinic, Cleveland, OH; ³Urology, Cleveland Clinic, Cleveland, OH
Living kidney donor transplantation is the preferred treatment for ESRD because it confers excellent outcomes for recipients and poses reasonable risks to donors. Post-donation glomerular…
2017 American Transplant Congress
Induction Therapy in Low Risk Elderly Kidney Transplant Recipients: Donor Factors.
F. Al Ammary, M. DeMarco, Q. Huang, E. King, S. Bay, A. Muzaale, A. Wiseman, D. Segev.
Johns Hopkins, Baltimore; University of Colorado, Denver
It is not known whether depleting induction is needed in low-risk elderly kidney transplant (KT) recipients in whom concern for infectious and complications is higher…